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Background: Asthma affects mainly Venezuela’s urban and poor majority. Exacerbations bring about a high
demand in health services, thus becoming a significant public health problem. In general, asthma control programs
(GINA) with use of inhaled steroid medications have proven effective, although their implementation in real life
remains cumbersome. Montelukast could be a useful and practical tool for these deprived socioeconomic sectors.
Methods: This real-life pilot study was conducted in a prospective, double blinded, placebo-controlled manner
with randomized and parallel groups. Asthmatics that had never used leukotriene modifiers were recruited and
followed-up every three months. The main outcome was the number of exacerbations meriting use of nebulized
bronchodilators administered by the health care system.
Results: Eighty-eight asthmatic patients were enrolled, between children and adults. Groups were comparable in:
demographic data, previous use of other medications, ACT scores, pulmonary functions (Wright Peak Flow meter),
allergy status (Skin Prick Test) as well as adherence to the prescribed Montelukast treatment. By an intention to treat
(ITT), a total of 64 patients were included for analysis. For the three and six months time points the difference
between placebo and Montelukast was found to be significant (p < 0.03 and p < 0.04, respectively). Such trends
continued for the rest of the year, but without statistical significance, due to patient attrition.
Conclusions: This real-life pilot study shows that a simplified strategy with oral Montelukast was practical and
effective in controlling exacerbations in an asthmatic population of a vulnerable community from Caracas. Such an
approach reinforces the role of primary care in asthma treatment.
Keywords: Asthma, Asthma exacerbations, Asthma control, Montelukast, Practical approach, Deprived urban
majorities, Venezuela, Latin AmericaIntroduction
Asthma in Venezuela is a public health problem, derived
from its high prevalence and significant impact due to
recurrent exacerbations [1-5]. About one third of asth-
matics share severe asthma characteristics [6]. Venezuela’s
population is predominantly urban (90%) and approxi-
mately half of it [7] lives under variable conditions of pov-
erty (Graffar Scale’sa D and E). Asthma prevails in such
deprived socioeconomic sectors [8] and a recent study of a* Correspondence: arnaldocapriles@gmail.com
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article, unless otherwise stated.vulnerable population in Caracas, reflecting its urban and
poor majority, supports such findings [9].
The increase in exacerbation rates for the past 20 to
25 years, represent asthma’s major impact; one million
acute episodes/year for 28 million inhabitants [2] is
compelling evidence (data from the Ministry of Health -
MoH - ambulatory network, caring for 80% or more of
the population). Furthermore, in such settings, asthma
exacerbations are often found second only to the febrile
syndrome and rarely overtaken by consultations for
diarrheas [2].
An existing National Asthma Control Program [1,2]
patterned after the Global Initiative for Asthma (GINA)
guidelines was last revised in 1998, but weaklyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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the use of inhaled medications [10] make, among other
considerations, a simplified asthma approach worth pur-
suing [11]. In analogy to oral rehydration therapies in
third world countries [12], use of an oral and for the
most part innocuous medication (Montelukast, MLK ),
seems particularly attractive for Venezuela’s urban and
poor majority context [8,9,11].
To address the impact from exacerbations a real-life
pilot project with Montelukast was carried-out, in a
double blinded placebo-controlled manner for six months,
to be further prolonged over a year-long period. Adher-
ence [10], educational needs, tobacco smoke exposure
[13] and sustainability in time were among the many is-
sues considered. Inaction is not an option regarding the
social determinants of asthma [10,14].
Materials and methods
This real-life pilot study was registered and audited
under number 090267 by the clinical trials department
of the Instituto Nacional de Higiene Rafael Rangel, an
official organization of the Venezuelan MoH. The Insti-
tutional Review Board of “Centro Médico de Caracas”
also approved this study. Funding was obtained from
LETI laboratories, in Caracas, Venezuela. The study was,
double blinded, randomized, and run in parallel groups.
Patients, including children with their representatives,
signed a consent form regarding the scope of the study
and the use of placebos. The “Los Erasos” slum was
chosen (see Figure 1) because it possessed [9] the living
conditions of 50% of the inhabitants of Caracas, the capital
city of Venezuela, and is located near the private medical
center. In addition, this community demonstrated in a
previous evaluative survey, the relationship between
asthma and poverty. A high prevalence of physician di-
agnosed asthma (15%) was found among its inhabi-
tants, with 2/3 of these patients in a non - control
status as determined by the ACT, for both children and
adults [9].
Asthma diagnosis also carried a recent history of fre-
quent extra-domiciliary nebulizations for acute symp-
toms relief. The existing health care system [2] provides
routine rescue treatments dispensed with nebulizations
of a Fenoterol/Ipatropium bromide inhalation solution
(0.25 mgs/0.5 mgs) at an age adjusted dosing (10 gtts
children - 20 gtts adults), diluted in 2–3 cc of 0.9%
saline. No patients were admitted at any stage of preg-
nancy, nursing or having had previous use of leukotriene
modifiers; however, any other therapy was allowed and
recorded. If during the course of the study a patient was
to become pregnant, she would have to be withdrawn
immediately. Patients and their families attended volun-
tarily and were invited to participate in the study by
means of information from slum community leaders andword of mouth from neighbors. Eagerly concerned fam-
ilies made for children numbers come close to half of
the participants, along with very few adult asthmatic
smokers.
The main variable was the number of exacerbations
(primary endpoint) needing rescue nebulizations with a
Fenoterol/Ipatropium combination administered at the
health care system; patients in need of assistance after
evening hours had to attend local hospitals nearby but
outside the community. Close monitoring of the primary
outcome was carried by monthly phone calls and de-
tailed questioning during regular visits. This project was
originally conceived for execution at the ambulatory
health facility (MoH) located within the community;
however, due to security concerns for the researchers, it
was carried out in a private medical office (ACH) across
the street, imposing limits on logistics particularly re-
garding number of participants.
A total of 88 known asthmatic patients (roughly 1/2
were children) were recruited. The patients were between
5 and 44 years of age, and were either smokers or non-
smokers. Those patients who had not smoked cigarettes
in the last 6 months were considered as non-smokers. The
daily consumption rate and the years of smoking were re-
corded for those who reported tobacco use. Asthmatics
between the ages of 5 and 12 were referred to as children,
while those 13 and up to 44 years of age were defined as
adults, in conformity with the ACT age ranges. These age
considerations helped avoiding confusion with other re-
spiratory syndromes, such as early ages viral wheezing and
chronic obstructive pulmonary disease in the elderly. This
does not imply however, the existence of asthma outside
of these age ranges.
Asthmatics underwent a detailed clinical history and
physical examination (with an emphasis on co-morbidities
such as allergic rhinitis and flexural atopic dermatitis).
Weight, height, body mass index, pulse and blood pres-
sure, together with prick skin tests (Lancetters, Hollister-
Stier) for inhalant allergens (Greer Labs, ALK-Abello)
were recorded during the examination. The best of three
standing Wright Peak Flow Meter measurements in L/min
(Ferraris Medical, Holland, New York, USA), not varying
by more than 5% and performed before and 20 minutes
after 400 mcg of albuterol, were obtained. Patients were
administered the ACT test according to age and received
minimal oral information and a simple written one-page
educational pictorial document.
Children received a 5 mg dosage of Montelukast daily
while adults received a 10 mg daily dosage. Montelukast
and placebo treatments were supplied in aluminum blister
packs (chewable tablets for those 4–15 years of age, 10 mgs
tablets for those 15–44 years of age), to be taken at night
prior to going to bed. The counting of empty blister packs
allowed for the estimation of adherence on return visits.
Figure 1 The first photo, taken from the nearby private medical facility, Centro Médico de Caracas, portrays living conditions of the
studied community. The second, an aerial photo, (below) provides a better insight into these aspects of Caracas.
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ceived a monthly phone call. During those calls they
were reminded to take the prescribed medication and to
follow recommendations on environmental control.
Likewise, emphasis was placed on the date of the next
hearing and on returning the blister aluminum packs for
proper evaluation of adherence. Furthermore, and most
importantly, they were urged to take note of exacerba-
tions that merited medical care (extra domiciliary) from
the local health care system.
This information was requested on every visit and
collated with the data obtained from the monthlyphone calls. Patients were allowed to take any other
suitable medications to treat their asthma (except leu-
kotriene modifiers), in an attempt to reflect a real life
situation; no further recommendations were given.
During follow-up visits, patients were questioned as to
whether their rhinitis had improved, had remained the
same or had worsened, as an indirect means of evaluat-
ing adherence.
Statistics
The sample size was calculated using as a reference a
study [15] of Infliximab vs placebo (Erin EM, Leaker
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antibody directed against tumor necrosis factor-alpha
in asthma. American Journal Respiratory Critical Care
Medicine 2006; 174 (7): 753–762). This study com-
pared the number of exacerbations (primary endpoint)
in asthmatic patients resulting in 72% of exacerbations
for the placebo group vs 29% for the Infliximab group.
We needed at least 30 patients per group to show a dif-
ference between the placebo and the Montelukast
treated group for a power of 80%. The percentage of
patients with acute exacerbations (primary end point)
was evaluated by the Chi square test. Alpha error level
for all variables was 5%.
Results
From the onset, the groups were comparable with regards
to the use of asthma medication, ACT test scores, WPFM
measurements and demographic data (age, sex, weight,
height, BMI, blood pressure and pulse). No patient had
previously used MLK; forty-six asthmatics comprised the
medication and forty-two the placebo group (Table 1).
During the intended first six months, the number of
patients allowed for significant statistical analysis, if children
and adults were grouped together. The loss of patients,
whereby only 19 of the initial 88 recruited patients com-
pleted the extended year-long treatment, did not permit
this.
Approximately 57% of the asthmatic patients had a
positive (> than 3 mm papule over negative control and
read at 10 min) prick skin test to a mixture of mites
(Dermatophagoides pteronyssinus/Dermatophagoides fari-
nae) as well as to Blomia tropicalis, which was in agree-
ment with what had previously been reported in Venezuela.
As well, lower rates of sensitization to other inhalant aller-
gens did not reveal (epithelia, molds, grasses, cockroach,
rodents) any significant difference between the groups.
In regards to the co-morbidities (average rhinitis diagno-
sis of 70% and flexural atopic dermatitis 8%) in patients and
the functional aspects for the diagnosis of asthma (revers-
ibility), no difference was observed among the groups.
In the case of children however, a better response toTable 1 Demographics
Montelukast Placebo p
Patients N° 46 42
Age 18,27+/-14,14 16,88+/-13,81 0,69*
Sex F/M 18/17 27/15 0,93**
Weight 47,16+/-25,11 45,96+/-28,49 O,91*
BMI 21,48+/-6,45 21.30+/_8,13 0.99*
Mite allergy 56.52 % 47.62 % 0.74**
Allergic Rhinitis 78.26 % 63.08 % 0.71**
*t student.
**Chi2.bronchodilatadors (>20% reversibility) was shown (80%).
There was a trend for improvement in the MLK group for
the WPFM and ACT scores, though no significant differ-
ences between the groups were detected during the year-
long study.
Following analysis allowed detecting, during the first
6 months, a significant difference between the groups in
the number of exacerbations needing assistance from
the health care system (Figure 2). Although there was
not a statistically significant difference in the second half
of the study, a continued tendency for fewer exacerbations
with the use of MLK, was observed. We believe this was
due to the small number of patients.
Adherence to the medication was between 80% and
90% for the three and six months time points, respectively,
with no significant differences observed between the
groups. By adherence we meant a return of 70% or more of
consumed tablets from the blister aluminum pack. Pa-
tients who received the active drug reported a significant
“improvement” in their rhinitis symptoms (yes/no) in
comparison with the placebo group. Three adverse effects
from the use of this medication were reported. Two oc-
curred in adults, and were mild and unrelated to the treat-
ment (one patient had a slight foot pain and the other had
an urticarial reaction that was medicated with Loratadine).
One child had diarrhea, but did not require suspension of
the treatment. An episode of diarrhea in an adult showed
up in the placebo group, which required suspension of the
treatment.
Discussion
Asthma in Venezuela is an important public health
problem [1,2,5] as evidenced by its high prevalence and
significant impact due to exacerbations. We attempted
to show that for Venezuelan’s urban and poor majority
context a reduction in the number of exacerbations
by regular use of Montelukast is an attainable goal.
Venezuela’s public health care system, however, persists




























Figure 2 Percentage of all patients with acute exacerbations in
need of rescue nebulizations at the local health system attended
by the group studied.
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with 90% living [7] in low socio-economic urban areas
which, according to a WHO operational classification,
can be considered as “slums” [16]. In addition, close to
50% of the population is classified under Graffar’s D and
E scale [7,17] where the greatest prevalence of asthma is
found [8,9]. Furthermore, asthma is a social disease [18]
demanding approaches that should not discard the varied
cultural elements surrounding it.
The number of asthma exacerbations has increased
significantly over the past 20 years [2,9] coming close
to a million acute asthma episodes/year. This surpasses
the number of exacerbations/year [19] in the USA (a
population ten times higher) by more than five times.
These asthma exacerbations occur primarily during
evening hours when these MoH outpatient health fa-
cilities [2,9] are closed and increased security issues
become more apparent. The significant absenteeism
from school and work, whereby 90% of children
suffering from acute asthma do not attend school and
50% of adults do not attend work, rounds up asthma’s
impact [9].
Venezuela’s National Asthma Control Program based on
the GINA guidelines (inhaled Beclomethasone) has been
only weakly implemented and not revised since 1998 [1,2].
Moreover, data from a non-profit organization (PROVEA,
2006) points clearly for asthma to be underfunded [8,20].
Since 2004, there has been a parallel health care system
run by Cubans [21], which addresses a portion of the
urban and poor majorities; however, no financial or clin-
ical information is available.
Successful asthma control strategies under the GINA
guidelines have been carried out in some areas of Latin
America [22]. Inconveniences around the use of steroid
inhaled medications [10] make for mitigating asthma ex-
acerbations with simpler yet effective strategies [23,24].
For these vulnerable urban and poor majorities, and in
analogy to oral rehydration therapies [12] for diarrheas
and dehydration, a paradigm for asthma is found wanting;
this study is conceived within these limits. Incidentally,
simplifying asthma treatments has been a cornerstone of
some of our previous efforts [25,26].
An important aspect of this real-life pilot study was the
double-blinded, placebo-controlled design with monthly
telephone calls for main outcome monitoring (asthma
exacerbations meriting the use of nebulized Fenoterol/
Ipatropium Bromide bronchodilators in the health care
system); nearly all urban households in Venezuela have
a cell phone-line [27]. Similar techniques have proven
useful in clinical settings [28] by increasing the degree
of reliability of predetermined outcomes. Patient groups
at entry were comparable in their demographics, ACT
scores, atopy (positive skin prick test to mites) and co-
morbidities.An unexpected drawback however, was the high attri-
tion rate of patients as the study progressed through the
final six months. It was acknowledged from the begin-
ning that this slum population was a hard one to study,
not discarding cultural elements for the high dropout
rate. The same was not carried out inside the commu-
nity boundaries; to attend the doctor’s office, patients
had to climb a series of long staircases, an element
which may have contributed to the high attrition rate.
One of the lessons learned, and an issue that must be
seriously considered for future similar projects in urban
and poor settings, is the need to maintain a high motiv-
ation level among local community leaders, patients and
families alike. Most importantly, any such program must
be conducted physically within the host community and
dealt “in situ” with any issues that may arise. These as-
pects were not given the weight they deserved given the
concerns pertaining to the researchers’ security.
The opportunity offered during an exacerbation to ver-
bally educate and succinctly reinforce concepts with pic-
torially written material, should be taken advantage of.
This may be the only contact an asthmatic in Venezuela
has with the health care system. A simple rule of two’s
(2′s) might serve [29] to discern which patients are in
need of asthma control treatments. Focus on primary
care remains pivotal when a simple approach as this is
used. Adherence issues, as with any asthma interven-
tions around the world, need to be dealt with local and
cultural factors. Sustainability in relation to cost issues is
an important consideration; the recent expiration of the
MLK patent [30] comes in rather conveniently if bulk
quantities are to be needed for large scale programs. An
IMS Health report for Venezuela [31] reveals a particu-
lar and interesting reality: a combination of a brand
name Fluticasone/Salmeterol 500/50 Diskus for a one
month treatment is 3 times more expensive than a
whole month of Montelukast 10 mgs tablets, such as the
one employed in this study (US$ 16 vs. US$ 5 respect-
ively). As a comparison, one pack of 20 cigarettes of a
common local brand costs US$ 1.3 and the minimum
monthly wage is set at US$ 82.5 (April 2014).
To conclude, we believe that simplifying the treatment
of asthma by aiming to reduce exacerbations can be
achieved with the administration of the oral medication
Montelukast. If these results are reproduced, they may
give a boost and allow for significant changes in the
National Asthma Control Programs and thus lessen the
impact that asthma exacerbations impose on the quality
of life of patients and families. Given the contributory
role that rhinitis [32] plays in the lack of control of asthma
symptoms, the recent availability in the Venezuelan
pharmaceutical market of a Desloratadine - Montelukast
combination [33] in one tablet (Desler M®), prompts
future research in this area. Though acknowledging the
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the right direction.
Endnote
aGraffar Scale is a widely applied index that divides
population in five descending layers (A through E) accord-
ing to a score of socioeconomic features [17].
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